Virus-Hit Astellas Cuts Forecast
But Top Seller Xtandi Remains Solid
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
You may also be interested in...
Join Jung Won Shin, Brian Yang and Ian Haydock in this recorded session from Informa Pharma Intelligence's recent 24-hour webinar series, COVID-19: Lessons Learned And A Path Forward.
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.